December 18, 2025
Educational Article: Implantation of anterior segment intraocular nonbiodegradable drug-eluting system
The only product on the market at this time is iDose. As this is a Category III code, claims will be billed on a case-by-case basis for medical necessity. Use should align with the current FDA indications. Off-label use includes repeat administration in an eye that has not received prior iDose TR. There is a paucity of evidence to support use in conjunction with other eye surgery or procedures. Insertion performed in conjunction with other surgeries will be reviewed for medical necessity and may be subject to denial.
CPT Codes
- 0660T: Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
- 0661T: Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant (Sunset January 2027)
HCPCS Code
J7355: iDose TR® – Not included with CPT code 0660T; bill separately.
ASC Billing
When billing for the Ambulatory Surgical Center (ASC) setting, the drug code is billed by the ASC who is providing the drug.
Office Billing
When billing for the office setting, the drug code is billed by the office who is providing the drug.
Inpatient Billing
When billing for the inpatient setting, the drug code is billed by the hospital who is providing the drug.
Recommended documentation includes:
- Diagnosis codes
- Documentation of intraocular pressure and other exam findings to support diagnosis
- Previous treatment, medical and surgical, for this condition
- Rationale for medical necessity for this treatment
- Absence of contraindications (as outlined in label)
- Place of service

